UBS Group AG - NUVECTIS PHARMA INC ownership

NUVECTIS PHARMA INC's ticker is and the CUSIP is 67080T108. A total of 9 filers reported holding NUVECTIS PHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
UBS Group AG ownership history of NUVECTIS PHARMA INC
ValueSharesWeighting
Q3 2023$48,672
-23.4%
3,776
-5.1%
0.00%
Q2 2023$63,545
+3077.2%
3,979
+1708.6%
0.00%
Q3 2022$2,000
+100.0%
220
+254.8%
0.00%
Q2 2022$1,0000.0%62
-56.0%
0.00%
Q1 2022$1,0001410.00%
Other shareholders
NUVECTIS PHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
BALDWIN BROTHERS LLC/MA 116,380$1,500,1380.13%
FORBES J M & CO LLP 34,000$438,2600.06%
Moran Wealth Management, LLC 16,697$215,2240.01%
Dorsey Wright & Associates 1,396$17,9940.01%
Tower Research Capital LLC (TRC) 7,282$93,8650.00%
MARSHALL WACE, LLP 36,085$465,1360.00%
Renaissance Technologies 25,400$3270.00%
UBS Group AG 3,776$48,6720.00%
RHUMBLINE ADVISERS 7,273$93,7420.00%
HOLLENCREST CAPITAL MANAGEMENT 280$3,6090.00%
View complete list of NUVECTIS PHARMA INC shareholders